The CHOP (cyclophosphamide/doxorucibin/vincristine/prednisone) regimen has been
established as the standard treatment for diffuse large B-cell lymphoma (DLBCL). With the …

Until now, literature data support the fact that the CHOP regimen represents the standard
first line treatment for patients with advanced intermediate-grade non-Hcdgkin's lymphoma …

For nearly 20 years CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) has
been the gold standard of therapy for aggressive non-Hodgkin's lymphomas (NHLs) …

Purpose: Randomized trial LNH93-3 was conducted on patients who had poor-prognosis
aggressive lymphoma and were younger than 60 years with two to three factors of the age …

This study was conducted to retrospectively identify the prognostic factors that specifically
predict survival rates of patients with aggressive non-Hodgkin's lymphoma who did not …

Purpose Long-term follow-up with updated time to disease progression (TTP) and duration
of response (DR) data are presented from a multicenter, phase II trial of rituximab …

Background The efficacy of autologous stem-cell transplantation during the first remission in
patients with diffuse, aggressive non-Hodgkin's lymphoma classified as high-intermediate …

Background CHOP is a first-generation, combination-chemotherapy regimen consisting of
cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately …

PURPOSE: To determine the safety and efficacy of the combination of the chimeric anti-
CD20 antibody Rituxan (rituximab, IDEC-C2B8; Genentech Inc, South San Francisco, CA) …

We conducted a randomized trial to compare the intensive conventional chemotherapy
regimen ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) with …